Amicus Therapeutics
Biotechnology company focused on developing treatments for rare metabolic diseases.
Check the tech stack behind amicusrx.com. Find a founder email at amicusrx.com.
About
Amicus Therapeutics is a global biotechnology company focused on advancing therapies to treat rare diseases. As a wholly owned subsidiary of BioMarin Pharmaceutical Inc., it is guided by people living with rare diseases and aims to redefine expectations in this field. The company's website highlights its work in research and pipeline development, including clinical trials and expanded access programs for its medicines. Teams look it up for Biotech, MedTech, HealthTech.
Frequently asked
What does Amicus Therapeutics do?
Amicus Therapeutics is a Biotech company that offers Biotech. Teams look it up for MedTech, HealthTech, Drug Discovery. It is based in Philadelphia, United States and was founded in 2002. Public records show about 625 people and $200M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Amicus Therapeutics raised?
Amicus Therapeutics has raised a total of $200M in funding. The most recent round on record is Series D.
Where is Amicus Therapeutics headquartered?
Amicus Therapeutics is headquartered in Philadelphia, United States.
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
What industry does Amicus Therapeutics operate in?
Amicus Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials.
How many employees does Amicus Therapeutics have?
Amicus Therapeutics has approximately 625 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.